Forward Therapeutics Announces Completion of Phase 1 Trials with Two Internally Discovered Next-Generation TNF Signaling Inhibitors Supporting Advancement to Phase 2 Clinical ...

Forward Therapeutics, Inc (“Forward” or “the Company”), a clinical-stage biotechnology company developing oral small molecule therapies for inflammation-driven diseases, today announced the successful ...
MarketBeat on MSN

Aclaris Therapeutics maps busy pipeline calendar, plans phase 2 asthma trial for ATI-052

Key Points Interested in Aclaris Therapeutics, Inc.? Here are five stocks we like better. Aclaris Therapeutics is preparing a ...

INmune Bio Reports Statistically Significant Treatment Effect on Advanced White Matter MRI Biomarker in Phase 2 MINDFuL Alzheimer's Trial

XPro1595 showed a highly significant treatment effect in the full mITT population (p=0.0028; d=0.46; n=200), demonstrating broad tissue-level target engagement and treatment-related biological effect.
Nasdaq

Chemomab Therapeutics Reports Promising Phase 2 SPRING Trial Data for Nebokitug, Showing Significant Improvements in Biomarkers for Primary Sclerosing Cholangitis and Other ...

Chemomab Therapeutics announced new findings from the Phase 2 SPRING trial that highlight the potential of their treatment, nebokitug, for primary sclerosing cholangitis (PSC) and other ...
Insider Monkey

New Data from the Phase II ARCHER Trial Demonstrate CardiolRx(TM) Improves Heart Structure in Patients with Acute Myocarditis, Supporting Expansion Across Inflammatory Cardiac ...

Phase II ARCHER trial showed a significant reduction in left ventricular (LV) mass (p=0.0117) and improvements in multiple key cardiac MRI (CMR) measures of structural heart recovery in patients with ...
Business Wire

Calluna Pharma Successfully Completes Phase 1 Clinical Study of CAL101, a First-in-Class Therapeutic for Fibrotic and Fibro-Inflammatory Indications

OSLO, Norway--(BUSINESS WIRE)--Calluna Pharma AS (Calluna), a clinical stage biotechnology company pioneering first-in-class antibodies to treat inflammatory and fibrotic diseases, today announced the ...